Skip to content
OpenCapital
Get started

DENTSPLY SIRONA XRAY Wellspect Healthcare — Adjusted research and development (“R&D”) expenses

Similar metrics at other companies

DuPont de Nemours, Inc. logo
DDHealthcare & Water Technologies — Research and development expenses
$22M+10.0%
Vishay Precision Group logo
VPGWeighing Solutions — Research And Development Expense
$1.48M+19.4%
Baxter International logo
BAXHealthcare Systems & Technologies — Research and development expenses
$49M+8.9%
Becton, Dickinson and Company logo
BDXConnected Care — Research and development expense
$90M+21.6%
OSI Systems logo
OSISHealthcare Division — Research And Development Expense
$4.63M+7.7%
Becton, Dickinson and Company logo
BDXMedical — Research and development expense
$130.75M+17.0%

Other financials

Income statement

See full
Revenue$880.0M+0.1%
Gross profit$427.0M-8.4%
Operating income-$35.0M-156%
Net income-$10.0M-150%
EPS (diluted)-$0.05-150%

Balance sheet

See full
Cash & equivalents$190.0M-52.3%
Total debt$2.3B-3.8%
Total equity$1.3B-34.4%
Total assets$5.2B-13.6%

Cash flow

See full
Operating cash flow$40.0M+471%
CapEx$52.0M+174%
Free cash flow-$12.0M0.0%

Valuation

See full
Market cap$2.11B-22.1%

Profitability

See full
Gross margin48.9%-2.6pp
Operating margin-14.1%-3.9pp
Net margin-17.1%-3.9pp
FCF margin2.8%-4.6pp

Returns & leverage

See full
Return on equity-37.7%+4.0pp
Debt / equity1.8×+0.6×
Current ratio1.5×+0.4×

Where this comes from

Reported directly by DENTSPLY SIRONA in its filing.

Tagged under the XBRL concept xray:ResearchAndDevelopmentExpenseAdjusted.

The official record: DENTSPLY SIRONA’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“r&d”) expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses?
DENTSPLY SIRONA (XRAY) reported wellspect healthcare — adjusted research and development (“R&D”) expenses of $3M in Q1 2026.
How has DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses changed year-over-year?
DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses increased by 50.0% year-over-year, from $2M to $3M.
What is the long-term trend for DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses?
Over 3 years (2022 to 2025), DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses has grown at a -11.5% compound annual growth rate (CAGR), from $13M to $9M.
What does wellspect healthcare — adjusted research and development (“R&D”) expenses mean?
Represents the investment made by the Wellspect Healthcare segment into product innovation, clinical research, and the development of new medical technologies. This metric is a key indicator of the segment's commitment to long-term competitiveness and future product pipeline growth.